Original text here
Medical robots are divided into surgical robots, exoskeleton rehabilitation robots and nursing robots. In the past few days, I have focused on the field of surgical robots. The overall feeling is that the domestic market for medical robots is huge, and there are not many good domestic companies. However, there are also companies with independent intellectual property rights like Tianzhihang. However, you need to be cautious about some listed companies labeling themselves “robots”.
The penetration rate of da Vinci in China is 4.3%
In the field of surgery, surgical medical robots have obvious advantages: less bleeding for patients, faster recovery, and shorter training time for doctors. Surgery will move from "resection" to the era of "repair". Therefore, surgical medical robots should be rapidly popularized in China in the next few years.
When talking about this field, we must first mention the "Da Vinci" produced by the American company Intuitive Surgical in 1999. It has been widely used in various surgeries such as prostate. There is a video on the Internet of Leonardo da Vinci sewing the skin of a grape delicately, which is amazing.
The penetration rate of Da Vinci in the hospital market in the United States has reached 47%. There are 4,974 community hospitals in the United States, and 2,344 units of Da Vinci have been installed. The penetration rate is 47%.
At the end of 2014, Da Vinci had 3,473 devices around the world, with revenue of US$2.13 billion and net profit of US$510 million in 2014. The company's market value has reached US$50 billion.
In 2014, Da Vinci's revenue structure included: new equipment sales of US$630 million; consumables of US$1.07 billion; and annual service fees of US$430 million (US$100,000-170,000 per unit per year). This revenue model has also become a model for other medical robot companies around the world.
In 2000, Leonardo da Vinci’s revenue was around US$20 million and its loss was US$18 million.
The 301 Hospital of the People's Liberation Army began to introduce da Vinci in 2006 and performed many operations. There are currently 6 Leonardo da Vinci machines in the 301 Hospital.
However, the price of each Da Vinci is about 20 million yuan, plus the cost of consumables and services. Ordinary hospitals can't afford it either. By the third quarter of 2015, there were 46 Da Vinci units in China, and there were 1,079 tertiary hospitals in China, with a penetration rate of 4.3%. From another perspective, this also shows that China's medical robot industry still has great potential.
In addition to Da Vinci, international medical robot brands include: Israeli Mazor Robotics' spine robot; French Medtech's neurosurgical positioning robot; American Curexo's joint robot; and American Mako's joint robot.
Beihang Zhihang leads the domestic market
Generally speaking, domestic medical robots are still in their infancy, and there is a big gap between them and Da Vinci. At the same time, the localization of surgical robots has begun.
The best domestic surgical robots include: Harbin Institute of Technology Sizherui, Beihang Zhihang, and Tianjin University Miaoshou Robot.
1. Beihang Zhihang
Tianzhihang is mainly in the field of orthopedics. Orthopedic surgeries do not involve internal organs, are easier to model, and are suitable for robots. Tianzhihang (834360) has been listed on the New OTC Market.
Surgical robots belong to the third category of medical devices. Clinical verification is required before a license can be obtained, and the time to obtain a license is 2-5 years. Tianzhihang products originate from the results of the 863 project jointly completed by Beijing University of Aeronautics and Astronautics and Beijing Jishuitan Hospital. Tianzhihang obtained the registration license for orthopedic robot products in February 2010 (State Food and Drug Administration Approval [2010] No. 3540188). This is my country's first medical robot product with completely independent intellectual property rights. The company has thus become the fifth company in the world to obtain a registration license for medical robots.
Currently in Beijing Jishuitan Hospital, 301 Hospital, Hebei Medical University Third Hospital, Shenzhen Second People’s Hospital, Zigong Fourth People’s Hospital, Beijing Haidian Hospital, Beijing Changping District Hospital, Xinjiang It has been applied in many medical institutions such as Karamay Central Hospital and Hebi People's Hospital.
Tianzhihang’s financial report in 2014 showed revenue of 38 million yuan and a loss of 12.7 million yuan.
2. Harbin Institute of Technology Sizherui
Sizherui is a company that develops minimally invasive laparoscopic surgical robots. The general manager of Sizherui is a professor at Harbin Institute of Technology and a researcher at Harbin Institute of Technology. Professor Du Zhijiang, deputy director of the institute. In May this year, Boshi Co., Ltd. invested 100 million yuan in 20% of Sizherui.
3. Tianjin University’s Miaoshou Robot
In 2014, Tianjin University successfully developed the “Miaoshou A Robot System”. This system is mainly used for minimally invasive abdominal surgery. In April last year, the Third Xiangya Hospital of Central South University was the first in China to use the "Miaoshou S" robot, performing gastric perforation repair and appendectomy on three patients.
A-share "robot concept stocks" have a lot of water
Domestic companies listed on A-shares have also labeled themselves as "robots". The main ones related to medical care are: Chutian Technology (300358), Boshi Technology (002698), HiSilicon (002653). However, judging from the situation of the following three companies, Boshi shares have a better foundation, while Truking Technology and HiSilicon only have a little bit of robot concepts.
(1) Trutian Technology
Trutian Technology cooperated with the National University of Defense Technology to develop an exoskeleton rehabilitation robot and launched a sample three years later.
(2) Haisco
Hisco spent US$10.5 million to subscribe for part of the shares of MST, an Israeli medical device company. MST's robot system is called "Autolap" and is mainly used for abdominal surgery. HiSco has obtained the sales agency rights of Autolap in China for 15 years.
(3) Boshi Co., Ltd.
Boshi Co., Ltd. is the industrialization base of the Robotics Research Institute of Harbin Institute of Technology. Harbin Institute of Technology is the most powerful institute in robotics technology in my country. In November 2013, Harbin Institute of Technology The "Minimally Invasive Abdominal Surgery Robot System" developed by the Robotics Research Institute has passed the acceptance of the national "863" program expert group.
Boshi Co., Ltd. invested 100 million yuan in a 20% stake in Harbin Institute of Technology’s “Minimally Invasive Surgical Robot and Intelligent Instrument Project” (Sizherui), and is expected to launch new products in 2016-2017.